NASDAQ$ESTA

Establishment Labs Holdings Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Establishment Labs experienced a mixed first quarter, with revenue decreasing year-over-year but gross profit margin increasing. Operating expenses were reduced, and the company is progressing towards FDA approval for Motiva Implants.

Establishment Labs reported a decrease in revenue for the first quarter of 2024 compared to the same period in 2023, but saw an increase in gross profit margin. The company reduced operating expenses and is making progress with FDA approval for Motiva Implants. Revenue guidance for 2024 remains between $174 million and $184 million.

  • First quarter worldwide revenue was $37.2 million.
  • Gross profit for the first quarter was $24.4 million, representing 65.6% of revenue.
  • Loss from operations was $8.8 million, improved from the fourth quarter of 2023.
  • Cash balance was $73.0 million as of March 31, 2024.

Headline financials

Total Revenue

$37.2M

Previous: $46.5M-20.1%
EPS

-$0.58

Previous: -$0.48-20.8%
Gross Margin

65.6%

No prior period
Capital Expenditures

-$3.31M

Previous: -$432K-666.7%
Free Cash Flow

-$19.5M

Previous: -$12.4M-57.7%
Net Income

-$16.2M

Previous: -$11.9M-35.7%
Operating Income

-$8.83M

Previous: -$8.16M-8.3%
Gross Profit

$24.4M

Previous: $30.1M-18.9%
Cash & Equivalents

$75.4M

Previous: $42.8M+75.9%
Total Assets

$302M

Previous: $209M+44.2%
R&D Expense

$4.27M

No prior period
Stock-Based Comp

$3.44M

Previous: $3.32M+3.6%

Revenue & EPS history

Establishment Labs · Revenue · Quarterly

$37.2M

Q1 2024-20.1%vs Q1 2023
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Forward guidance

Establishment Labs anticipates continued improvement throughout the year, driven by market stabilization and expense reduction initiatives. The company expects U.S. FDA approval of Motiva this year and is preparing for the launch.

Tailwinds

  • Market demand is stabilizing.
  • Continued improvement is expected over the course of the year.
  • Meaningful steps have been taken to reduce the expense base.
  • Adjusted EBITDA improved significantly.
  • U.S. FDA approval of Motiva is expected this year.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+1.5%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+2.4%

Avg return

30 days after

56%

18 / 32 earnings

Positive

+22.5%

Q3 2025

Best reaction

-26.0%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.4%-4.3%+2.9%
Q4 2025-1.9%+5.0%-20.1%
Q3 2025+22.5%+37.0%+43.2%
Q1 2025+4.9%+5.1%+14.2%
Q4 2024+17.9%+28.1%+12.1%
Q3 2024-5.2%-13.2%-10.0%
Q2 2024+3.4%+20.6%+23.5%
Q1 2024+5.4%+4.2%-10.8%
Q4 2023+15.1%+19.6%+28.2%
Q3 2023-26.0%-36.1%-31.7%
Q2 2023-8.4%-12.0%-12.2%
Q1 2023+1.8%-1.6%-1.9%
Q4 2022+7.2%+10.3%+0.3%
Q3 2022-7.7%+11.1%+27.1%
Q2 2022-3.0%+1.3%-0.4%
Q1 2022-10.5%-10.1%+2.3%
Q4 2021+3.3%+1.6%+11.5%
Q3 2021-10.6%-14.3%-15.2%
Q2 2021+6.0%-3.7%-3.1%
Q1 2021-0.6%-1.8%+8.9%
Q4 2020+0.4%-6.8%+9.5%
Q3 2020+8.9%-0.4%+22.6%
Q2 2020+6.2%+7.3%+9.3%
Q1 2020+2.9%+0.5%+15.3%
Q4 2019+4.5%-16.4%+0.4%
Q3 2019-0.3%+0.5%+7.8%
Q2 2019-5.2%-10.6%-10.2%
Q1 2019+1.5%-0.3%-15.9%
Q4 2018-1.9%-4.9%-15.2%
Q3 2017+10.3%+4.5%-6.2%
Q3 2018+10.3%+4.5%-6.2%
Q2 2018-2.7%-2.9%-3.4%
Q4 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro